Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52516 | 0.89 | BRD4 (0.51) | BRD4GAATSHRTHRBKMT2A | |
| SCHEMBL19052803 | 0.89 | BRD4 (0.51) | BRD4GAATSHRTHRBKMT2A | |
| SCHEMBL16969313 | 0.83 | BRD4 (0.43) | BRD4GAA | |
| SCHEMBL24197361 | 0.83 | BRD4 (0.50) | BRD4GAATSHRKMT2AALDH1A1 | |
| SCHEMBL2036054 | 0.83 | — | — | |
| SCHEMBL26647720 | 0.83 | BRD4 (0.50) | BRD4GAATSHRKMT2AALDH1A1 | |
| SCHEMBL28304479 | 0.82 | BRD4 (0.45) | BRD4GAATSHRKMT2AALDH1A1 | |
| SCHEMBL2257497 | 0.81 | KMT2A (0.41) | GAATSHRKMT2AALDH1A1HSD17B10 | |
| SCHEMBL9054489 | 0.81 | TSHR (0.43) | BRD4TSHRKMT2AALDH1A1EPHX2 | |
| Ammonia Solution, Strong SCHEMBL27687914 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3947334-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-29 | — | — | EP | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119708121-A | Amide compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4491625-A1 | BENZO BICYCLIC COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | Guangzhou Unirise Pharmaceutical Co., Ltd. (CN) | 2025-01-15 | — | — | EP | disclosed |
| US-12195698-B2 | Fragrance compound providing lily of the valley fragrance characteristics, and fragranced compositions comprising the same | GIVAUDAN SA (CH) | 2025-01-14 | — | — | US | disclosed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| CN-113853371-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117940133-A | Therapeutic agents for degradation of mutant BRAF | C4医药公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-1904435-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | Amgen Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007138435-A2 | A PROCESS FOR THE PREPARATION OF DISPIRO 1,2,4-TRIOXOLANE ANTIMALARIALS (OZ277) | RANBAXY LABORATORIES LIMITED (IN) | 2007-12-06 | — | — | WO | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | JAPAN TOBACCO INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-7244727-B2 | Fused bicyclic nitrogen-containing heterocycles | JAPAN TOBACCO INC. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244727-B2 | Fused bicyclic nitrogen-containing heterocycles | JAPAN TOBACCO INC. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006138508-A2 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20050256185-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2005-11-17 | — | — | US | disclosed |
| US-4816453-A | N-heterocyclic derivatives of benzamides and their use in treating gastric and intestinal disorders | BEECHAM GROUP, P.L.C. (GB) | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | BRD4 1544/4885GAA 1007/4885TSHR 1660/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | BRD4 1544/4885GAA 1007/4885TSHR 1660/4885 |
| US-12195698-B2 | Fragrance compound providing lily of the valley fragrance characteristics, and fragranced compositions comprising the same | MDH2, MDH1, TRPV1 | BRD4 1842/4885GAA 3886/4885TSHR 4765/4885 |
| US-20070244096-A1 | Fused Bicyclic Nitrogen-Containing Heterocycles | PC, HCCS, MYC | BRD4 194/4885GAA 1223/4885TSHR 3488/4885 |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | BRD4 184/4885GAA 131/4885TSHR 723/4885 |
| US-20250042883-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | BRD4 3056/4885GAA 1538/4885TSHR 284/4885 |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | BRD4 1544/4885GAA 1007/4885TSHR 1660/4885 |
| US-20050256185-A1 | Spiro and dispiro 1,2,4-trioxolane antimalarials | DHODH, THPO, SQLE | BRD4 3527/4885GAA 4160/4885TSHR 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.